News|Articles|September 23, 2026

Pharmacy Practice in Focus: Oncology

  • October 2026
  • Volume 8
  • Issue 7

After 180 Years, Multiple Myeloma Gets a Definition of Cure

Fact checked by: Ron Panarotti
Listen
0:00 / 0:00

Key Takeaways

  • CARTITUDE-1 data showing ≥5-year remission after 1 cilta-cel infusion accelerated acceptance that a subset of MM can achieve durable, potentially curative outcomes.
  • The IMWG definition requires 5 years of complete remission off all myeloma therapy, with timing measured from treatment cessation rather than first achieving CR on therapy.
SHOW MORE

For as long as practicing oncology pharmacists have been in the field, multiple myeloma has carried a standard caveat: treatable, not curable—now that is changing.

The word cure was seldom used in multiple myeloma (MM) until the CARTITUDE-1 trial (NCT03548207), which showed that a single infusion of ciltacabtagene autoleucel (cilta-cel, Carvykti; Janssen Biotech, Inc/Legend Biotech) led to 5-year remission in one-third of patients.1

These results led the International Myeloma Working Group to update its consensus definition. Now, newly diagnosed or relapsed/refractory MM (NDMM, RRMM) may be considered cured after 5 years in complete remission without any treatment.2 The shift is notable for a disease that has historically been difficult to treat and fatal, offering many patients new hope.

“For many years, multiple myeloma has been described as treatable but not curable. Today, scientific advances have brought us closer to defining what cure means,” said Nikhil C. Munshi, MD, a founding member and immediate past president of the International Myeloma Society, a professor of medicine at Harvard Medical School, the Kraft Family Chair at Dana-Farber Cancer Institute, and director of basic and correlative science at Dana-Farber Cancer Institute’s Jerome Lipper Multiple Myeloma Center. “The depth and durability of responses we are now seeing, along with major progress in [minimal residual disease] testing and modern therapies, have moved the field to a point where we can see that a cure exists and examine how it should be defined.”2

What Does the New Consensus Establish?

The new definition sets a 5-year bar, but it is a specific and fairly demanding 5 years. A patient with NDMM or RRMM may be considered cured after 5 years in complete remission with no myeloma treatment at all. The clock starts when treatment stops, not from whenever the patient first became disease-free while still being treated. Ongoing drug therapy does not count; the definition is built specifically to separate a durable, unassisted remission from a well-controlled chronic disease.2

To meet the bar, patients need all the following2:

  • At least 4 negative minimal residual disease (MRD) tests, including 1 at the 5-year mark, with no positive result anywhere in between
  • MRD testing sensitive enough to detect 1 myeloma cell in 1 million, using next-generation sequencing (NGS) or next-generation flow (NGF)
  • Advanced imaging (PET/CT or diffusion-weighted whole-body MRI) showing no disease at the start and end of the observation period, with no positive scan at any point if additional imaging is performed along the way

How Will This Affect Pharmacists?

For oncology pharmacists, a formal cure definition isn’t just semantics—it reframes several practical conversations that come up constantly in myeloma care:

MRD testing becomes a treatment-duration question, not just a prognostic one. The definition explicitly requires 4 consecutive negative results using 10-6–sensitivity NGS or NGF testing. As MRD-adapted treatment and maintenance-discontinuation strategies (such as those being tested in MIDAS [NCT04934475] and reported in PERSEUS [NCT03710603] long-term follow-up) become more common, pharmacists are going to be fielding more questions from patients about whether a given MRD result means treatment could eventually stop altogether—and this framework gives that conversation actual criteria to point to, rather than a vague “We will have to see.”2

“Off treatment” is now a defined clinical end point, not just a patient preference. Distinguishing a drug-free cure from a drug-controlled remission has direct implications for how aggressively maintenance therapy is pursued and for how patients and clinicians think about the trade-offs of stopping therapy early vs continuing indefinitely.2

Set expectations with patients changes. A disease that’s been described as incurable for nearly 2 centuries now has a rigorous, named threshold that some patients may realistically be counted toward. That is a meaningfully different conversation to have at the infusion chair or during a maintenance-therapy consult than the treatable-but-not-curable framing pharmacists have relied on for years.2

“We are no longer debating whether a cure is possible,” Munshi said. “We are defining it rigorously, measuring it precisely, and expanding the number of patients who can achieve it—with clarity, discipline, and real hope.”2

REFERENCES
1. Jagannath S, Martin T, Cohen A, et al. Long-term (≥5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma. J Clin Oncol. Published online June 3, 2025. doi:10.1200/JCO-25-00760
2. Munshi N; International Myeloma Society; International Myeloma Working Group. IMS/IMWG consensus definition of cure in multiple myeloma. Presented at: 23rd International Myeloma Society Annual Meeting; September 23-26, 2026; Glasgow, Scotland.

Related to this article